Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) and VitaHealth BV have agreed to offer the Nightingale Remote Health Check in the Netherlands. VitaHealth provides the test, including disease risk assessments, metabolic scores, and blood values, to private individuals, employers and occupational health services, and lifestyle medicine professionals. The test was launched at a conference at Lifestyle Centre Haaglanden in October 2026.

Nightingale Health Plc | Press Release | November 10, 2026 at 09:00:00 EET

Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) and VitaHealth BV have agreed to offer the Nightingale Remote Health Check in the Netherlands. VitaHealth provides the test, including disease risk assessments, metabolic scores, and blood values, to private individuals, employers and occupational health services, and lifestyle medicine professionals. The test was launched at a conference at Lifestyle Centre Haaglanden in October 2026.

Under the agreement, VitaHealth offers the test through its service, and Nightingale Health analyses the blood samples. From a single finger-prick blood sample, the Nightingale Health Remote Check produces a 10-year risk estimate for multiple chronic diseases, including heart disease, type 2 diabetes and fatty liver disease. Upon the choice of the person, the report includes these risk scores and overall health scores such as the person's Metabolic Age and Metabolic Resilience Score, and shows their blood values, including lipids, fatty acids, amino acids, sugar metabolism, and chronic inflammation. A VitaHealth medical expert team goes through the results and a doctor explains the report for the person and turns them into a lifestyle plan. The test can be repeated after following the plan to see how the person's risks and blood values change.

VitaHealth is a Dutch societal company whose mission is to add healthy years to people's lives. Most people hear about their health only when symptoms appear; VitaHealth measures first and then helps the person improve. The company offers the same test to three groups. Private individuals use it to learn their disease risks and their biological age. Employers and occupational health services offer it as an objective measure for their employees to check their health and the effect of their wellbeing programmes where employees own their results. Healthcare professionals use it as a validated baseline and follow-up in prevention and lifestyle medicine. The launch marks Nightingale Health's entry into the Netherlands.

"Broad biomarker tests have existed for years, but they stayed in research laboratories and expensive clinics. We want everyone to be able to know how their body is doing before symptoms appear. The Nightingale Health Check gives our clients a clinically validated picture of their disease risks and blood values. Our doctors then turn that picture into a plan to empower the person to change their lifestyle, feasible to follow," says Guus Vaassen, CEO of VitaHealth.

"Disease risk builds up for years before symptoms appear, and the earlier people know their risks, the more they can do about them. With VitaHealth, people in the Netherlands can now learn their disease risks from one blood sample, whether they order the test themselves, receive it through their employer, or take it with their doctor. The Netherlands is a new market for us, and VitaHealth is a strong partner to start with," says Teemu Suna, CEO and Founder of Nightingale Health.

About VitaHealth

VitaHealth BV is a Dutch societal enterprise company with one mission: to add healthy years to people’s lives.

VitaHealth serves private individuals, employers and occupational health services, and healthcare professionals who use the test as a validated baseline and follow-up in prevention and lifestyle medicine. The metabolic scores used are developed by Nightingale Health. VitaHealth’s scientific expert team is chaired by Prof. Eline Slagboom, Professor of Molecular Epidemiology at LUMC, including Dr. Joris Deelen, associate professor in the same group.

VitaHealth builds on more than ten years of Dutch scientific research with the assays performed on the Nightingale Health platform. Since the mid-2010s, LUMC researchers have measured the Nightingale metabolite assay in tens of thousands of participants of Dutch population studies to investigate how robust these predict the decline of global health a decade before the first disease diagnoses. VitaHealth itself originated as a spin-out of publicly funded research: in 2024, the Dutch government’s health research organisations ZonMw and Heath Holland asked the founders to explore whether the scientific advances resulting from the VOILA public private initiative headed by professor Slagboom could be turned into a social enterprise that makes them available to the public.

VitaHealth was founded by a physician and lifestyle doctor, a pharmacist-entrepreneur and a data entrepreneur, and is based in Klarenbeek, the Netherlands. The launch in the Netherlands is a first step: VitaHealth has international ambitions and is actively seeking partnerships with organisations that want to combine lifestyle and biomarkers, from lifestyle and prevention programmes to healthcare providers and employers who want to measure the effect of their approach. More information: https://www.vitahealth.nl/en/

For VitaHealth enquiries: press@vitahealth.nl

For further information, please contactTeemu Suna, CEOir@nightingalehealth.com

About Nightingale HealthChronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.

Nightingale Health's technology is validated in over 1,000 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 250,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the regulated market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/

Image AttachmentsNightingale Health